Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04603131
Other study ID # BBIL/CHIKV/I/2014
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date April 17, 2017
Est. completion date July 30, 2018

Study information

Verified date October 2020
Source Bharat Biotech International Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chikungunya vaccine is an inactivated virus vaccine. There will be three study arms and subjects will be vaccinated in a dose escalation manner.In each arm, vaccine will be administered on Day 1, Day 29, and Day 57. Vaccine will be administered through intramuscular route.


Description:

This is an open label phase I study for assessing the safety, tolerance and immunogenicity of 3 escalated doses of the test vaccine, BBV87. The study design has four treatment groups - 3 test groups and a control placebo group with 15 subjects in each group. However, the groups will be divided into three study arms: each arm will have 15 subjects of the test vaccine group and 5 subjects of the placebo group. The randomization will be done in a way that allots 5 subjects of the placebo group to each test dose group. All subjects will be screened (via medical history, physical examination and laboratory investigations) to establish the eligibility criteria. This includes negative antibodies, CHIKV IgG, by ELISA method. The test vaccine and placebo will be administered as 3 doses at 28 days interval on day 1±2, 29±2, and 57±2. Vaccine administration will be performed as an in-patient procedure. Subjects will be admitted in CPU 24 hrs prior to vaccine administration, and will be shifted to MICU for vaccination and observed for 48 hrs; and will be discharged upon completion of all clinical monitoring procedures. Laboratory and biochemical tests will be performed as part of clinical monitoring before discharge, and 24 hrs after vaccine administration. Following vaccination, all participants will be monitored throughout the study period for adverse events with daily telephone contacts (for 7 days after each vaccine, and then weekly), interim clinic visits, subject diary cards, and haematological & biochemical laboratory tests.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date July 30, 2018
Est. primary completion date January 30, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - =18 and =50 yrs inclusive on the day of screening - Able and willing to complete informed consent process with understanding of the purpose and procedures of the study - Medical history and physical examination without clinically significant findings at the time of screening - Haematological and biochemical values either within institutional normal range and accompanied by physician approval - Agree to keep a daily record of symptoms for the duration of the study - Available for clinical follow-up throughout the study period via telephone contact as well as clinic visits Female specific criteria: - If female of child bearing potential- have a negative urine pregnancy test result within 24 hrs of the scheduled first vaccination Exclusion Criteria: Female specific criteria: - Woman who is breast feeding or planning to become pregnant during the study period. General Criteria: - History of suspected or confirmed Chikungunya fever (Case definition for Suspected Chikungunya: A subject meeting both the clinical and epidemiological criteria. - Clinical criteria: acute onset of fever >38.5°C and severe arthralgia/arthritis not explained by other medical conditions. - Epidemiological criteria: residing or having visited epidemic areas, having reported transmission within 15 days prior to the onset of symptoms. Case definition for Confirmed Chikungunya: A subject meeting the laboratory criteria of positive ELISA test for CHIKV IgG.) - Clinically significant abnormal clinical laboratory values including blood pressure(>140 mmHg systolic and >90 mmHg diastolic) when 3 measurements are taken 30 min apart , in seating position and at rest - Body mass index (BMI) = 25 [BMI will be calculated as weight in Kilograms/(height in metres)2] - Test positive for HIV or Hepatitis B infection - History of cardiovascular disease - History of immune deficiency or autoimmune disease - Have active or history of arthritis (joint swelling, pain, tenderness, warmth or erythema) within the last 6 months from date of screening - Have an active or history of malignant conditions including haematological malignancy - Have a history of degenerative neurological disease (e.g. GuillainBarre Syndrome, multiple sclerosis) - Have received any vaccination within 4 weeks prior to the vaccination in this study - Have received blood transfusion or immunoglobulin within 30 days prior to vaccination in this study - Have a history of serious reactions to any vaccines that preclude receipt of study vaccinations as determined by the investigator - Have asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that is expected to require the use of oral or intravenous corticosteroids - Have diabetes mellitus (type I or II), with the exception of history of gestational diabetes - Have received any investigational drug in 6 weeks prior to screening - Is currently participating in any form of clinical trial that involves intervention. - Is likely to participate in any other clinical trial during the study period.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Inactivated Chikungunya virus vaccine 20 mcg
3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
Inactivated Chikungunya virus vaccine 30 mcg
3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
Inactivated Chikungunya virus vaccine 10 mcg
3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
Placebo
3 doses of Placebo administered intramuscularly on Day 0, 29 and 57

Locations

Country Name City State
India Panchsheel Hospital Delhi
India Medanta - The Medicity Gurgaon Haryana
India KEM Hospital Mumbai Maharastra
India King George Hospital Visakhapatnam Andhra Pradesh

Sponsors (1)

Lead Sponsor Collaborator
Bharat Biotech International Limited

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of adverse events and Serious Adverse events post each dose safety Within 24 hrs
Primary Occurrence of adverse events and Serious Adverse events post each dose safety 7 Days,
Primary Occurrence of adverse events and Serious Adverse event 28 days after the last dose of vaccine safety 9 months
Secondary Immunogenicity in terms of GMT estimated by 50 percent plaque reduction neutralization test Immunogenicity day 28
Secondary Immunogenicity in terms of GMT estimated by 50 percent plaque reduction neutralization test Immunogenicity day 56
Secondary Immunogenicity in terms of GMT estimated by 50 percent plaque reduction neutralization test Immunogenicity day 84
Secondary Proportion of subjects with four fold seroconversion Immunogenicity day 28
Secondary Proportion of subjects with four fold seroconversion Immunogenicity day 56
Secondary Proportion of subjects with four fold seroconversion Immunogenicity day 84
See also
  Status Clinical Trial Phase
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT04440774 - Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico. Phase 1
Completed NCT05153018 - Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu N/A
Active, not recruiting NCT04343521 - Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases Phase 3
Completed NCT03992872 - Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) Phase 2
Completed NCT03382964 - Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Phase 1
Completed NCT02831699 - The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
Recruiting NCT01099852 - Cohort of Patients Infected by an Arbovirus
Completed NCT06257810 - Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa Phase 4
Suspended NCT05218304 - Baromètre Santé Adulte 2021-2022 N/A
Recruiting NCT04615364 - Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Completed NCT04650399 - A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents Phase 3
Not yet recruiting NCT04672577 - Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
Completed NCT04434846 - Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
Recruiting NCT04838574 - Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Recruiting NCT04619823 - Virological and Immunological Determinants of Arbovirus Infection in New Caledonia N/A
Completed NCT03101111 - Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area Phase 2
Completed NCT02463968 - Chikungunya Arthritis in the Americas N/A
Active, not recruiting NCT04566484 - Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia Phase 2/Phase 3